中文

← All funding rounds

BioGeometry

ChinaProtein designBeijing, ChinaFounded 2022Private

Website · biogeom.com ↗

Builds generative models for biology: GeoFlow, an all-atom model that predicts the structures of proteins and their complexes and designs binders, and GeoCell, a virtual-cell model of how cells' gene expression responds to genetic and drug perturbations. An automated lab expresses and tests the designs and feeds the data back. It designs antibodies, vaccines, peptides and enzymes for partners and its own pipeline, including synthetic-biology products.

Disclosed total-
Rounds on record3
Latest roundnot disclosed; the A series to date tops $100MSeries A+ · 2026-10-28
Last stated valuationNone stated
Investors named13
Research on recordNone yet

Money and evidence

Moneyeach round in US dollars; ≈ converted at its date20252026Pre-Series AStrategic roundSeries A+
Closed roundNot on the dollar scale (a range, or no rate)

No research by this company is on the record yet.

Rounds and research, on one timeline

  1. 2026-10-28Series A+
    Round

    not disclosed; the A series to date tops $100M

    For: keep developing the GeoFlow molecule model and the GeoCell cell model, expand its high-throughput automated lab, and bring its own pipeline to market

    Models and platformAutomated labCommercial roll-out

    The company announced it through PEdaily, with China Life Capital and the Shanghai fund quoted. The announcement calls the Shanghai fund by a short name, Shanghai Biomedical Fund, and adds unnamed leading biopharma companies among the participants.

    Lead · China Life CapitalGuokai KechuangRuili InvestmentGuofang CapitalExisting investor · Shanghai Biomedical Innovation FundExisting investor · Fortune Venture Capital

    On the deal: Qiushan Guo (Partner; spoke for the fund in the announcement, Shanghai Biomedical Innovation Fund)

    Advisers: Index Capital (exclusive financial adviser)

    Announced by the company · news.pedaily.cn ↗On the timeline →

  2. 2026-06-09Strategic round
    Round

    several hundred million yuan

    For: keep developing the GeoFlow model and advance its own drug pipeline

    Models and platformToward the clinic

    36Kr's first report, with Jian Tang quoted, read on Tencent News; PEdaily (https://news.pedaily.cn/202606/565025.shtml) names the same investors and quotes four of them. The October announcement counts this round in the A series.

    Co-lead · Shanghai Biomedical Innovation FundCo-lead · Guoke InvestmentCo-lead · Fortune Venture CapitalCo-lead · Xinglian CapitalGaorong CapitalIndex AI Industry Innovation Fund

    On the deal: Dakui Wang (Managing Director; spoke for the firm, Fortune Venture Capital); Kun Zhang (Head of the smart healthcare group; spoke for the firm, Guoke Investment); Qiushan Guo (President; spoke for the fund, Shanghai Biomedical Innovation Fund); Wenjue Li (Partner; spoke for the firm, Xinglian Capital)

    Advisers: Index Capital (exclusive financial adviser)

    Announced by the company · view.inews.qq.com ↗

  3. 2024-06-19Pre-Series A
    Round

    undisclosed

    For: bring its generative protein models into biomanufacturing and develop its own products

    Models and platformCommercial roll-out

    The company's announcement on PEdaily, with Jian Tang and Jiangmen Ventures quoted; it gives no amount and names the existing investor as Gaorong Ventures.

    Lead · Jiangmen VenturesZhipu AIShengjing JiachengExisting investor · Gaorong Capital

    On the deal: Xinxin Gao (Founding Partner; spoke for the lead in the announcement, Jiangmen Ventures)

    Announced by the company · news.pedaily.cn ↗

Research entries are the timeline's graded entries that name this company. A level grades one claim, not the company, and a blank can mean the record has not caught up rather than that nothing was published.

See these rounds in the table →

Its investors also backed

Other companies on this page whose rounds name the same investor.